AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has blessed the PD-L1 inhibitor for limited-stage small cell lung cancer (LS-SCLC) ...

Imfinzi is the first perioperative immunotherapy approved for resectable gastric/GEJ cancers, offering a new treatment ...

FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits.

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. This time, a groundbreaking FDA approval makes the PD-L1 inhibitor the first immunotherapy ...

FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC trial. Imfinzi shows median overall survival of 55.9 months versus 33.4 ...

The US Food and Drug Administration approved AstraZeneca’s Imfinzi (durvalumab) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, ...

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...

AstraZeneca’s (AZN) Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC, whose disease has not progressed ...

Top-level phase 3 data on AstraZeneca's Imfinzi (durvalumab) showed statistically significant improvement in pathologic complete response compared to neoadjuvant chemotherapy alone in gastric and ...